5-HT2B antagonist
5-HT2B serotonin receptor antagonist
- No established major therapeutic or adverse consequence
- May be protective — the opposite of the valvulopathy-causing agonists
Drugs with this mechanism (7)
- Aripiprazole — D2 partial agonist; weight-favorable, activating, low prolactin; can cause akathisia.
- Aripiprazole lauroxil LAI — Long-acting aripiprazole prodrug injection for schizophrenia; requires a loading strategy.
- Aripiprazole lauroxil LAI — Rapid-start aripiprazole lauroxil injection used only to initiate Aristada treatment.
- Aripiprazole monohydrate LAI — Extended-interval aripiprazole LAI for schizophrenia and bipolar maintenance.
- Aripiprazole monohydrate LAI — Long-acting aripiprazole for schizophrenia and bipolar maintenance; akathisia remains prominent.
- Desmethylcariprazine — Cariprazine metabolite with the same D3-preferring partial agonism as the parent.
- Didesmethylcariprazine — Cariprazine's long-lived second metabolite — the reason steady state takes weeks and washout takes longer.
Self-check
- Is a major therapeutic or adverse consequence of 5-HT2B blockade established?
No. - Name a listed drug with 5-HT2B antagonist activity.
Aripiprazole.
All mechanisms · Open 5-HT2B antagonist in the interactive console ↗